PeerView Gastroenterology CME/CNE/CPE Video Podcast
By PVI, PeerView Institute for Medical Education
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Category: Science
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 10
Reviews: 0
Episodes: 59
Description
PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
| Episode | Date |
|---|---|
|
Mirna Chehade, MD, MPH, AGAF, FAAAAI / Evan S. Dellon, MD, MPH - Early Diagnosis and Evolving Management of Eosinophilic Esophagitis in the Era of Targeted Therapy
|
Nov 22, 2024 |
|
Jennifer Chan, MD, MPH - Renewed Optimism for Personalized Care in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors: The Evolving Role and Clinical Applications of Emerging Strategies to Improve Patient Outcomes
|
Nov 21, 2024 |
|
Andrea Cercek, MD - Accelerating Personalized Care in CRC: The Prominent Role of Predictive Biomarkers and Immunotherapy Platforms in Early and Advanced Disease
|
Nov 12, 2024 |
|
Arndt Vogel, MD, PhD - Strengthening the Immunotherapy Paradigm in Biliary Tract Cancer: Standardizing Team-Based Strategies With Immune Checkpoint Inhibitors in Advanced Disease
|
Oct 22, 2024 |
|
Angela Lamarca, MD, PhD, MSc - Prioritising Patient-Centric Care in Biliary Tract Cancer: Leveraging Immunotherapy Platforms to Overcome Challenges in the Advanced Setting
|
Aug 15, 2024 |
|
Yelena Y. Janjigian, MD - Precision Tactics in HER2-Positive GI Malignancies: Capitalizing on HER2-Targeted Regimens to Improve Outcomes for Gastric/GEJ Cancers, CRC, and BTC
|
Jun 24, 2024 |
|
Manish A. Shah, MD, FASCO - Catalysts for Change in Gastric and GEJ Cancer: Digesting New Evidence and Future Directions of Care With Innovative Immunotherapy and Targeted Platforms
|
Jun 24, 2024 |
|
Rohit Loomba, MD, MHSc - Experts vs AI: Who Is Better at Monitoring and Treating MASLD and MASH?
|
Jun 11, 2024 |
|
Riad Salem, MD, MBA / Mark Yarchoan, MD - Establishing the Collaborative Benchmark for HCC Care: Critical Discussions Between Interventional Radiologists and Oncologists to Maximize Therapeutic Benefit
|
Jun 11, 2024 |
|
Saakshi Khattri, MBBS, MD, FAAD, FACR - Interdisciplinary Approaches to Management of Immune-Mediated Inflammatory Diseases: Addressing Shared Pathophysiology With JAK Inhibitors
|
May 10, 2024 |
|
Lipika Goyal, MD, MPhil / Riad Salem, MD, MBA - The Convergence of Interventional Radiologists and Oncologists in HCC: Shared Decision-Making and Care Coordination at the Center of Personalized Care Across the Disease
|
Apr 17, 2024 |
|
Joshua B. Wechsler, MD, MSci - Targeting a Brighter Future for Pediatric Patients With Eosinophilic Esophagitis: Ensuring Prompt Diagnosis and Exploring the Role of Biologic Treatment
|
Feb 27, 2024 |
|
Lipika Goyal, MD, MPhil / Riad Salem, MD, MBA - Synergizing for Success in HCC: Immunotherapy Advances and the Role of the Interventional Radiologist-Oncologist Collaboration Across the Disease Continuum
|
Feb 21, 2024 |
|
Milind Javle, MD - Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice
|
Feb 20, 2024 |
|
Jaffer A. Ajani, MD, FASCO - Looking Beyond the Horizon in Gastroesophageal Cancers: Updated Evidence on How Systemic Therapies Are Redefining Care
|
Jan 31, 2024 |
|
John L. Marshall, MD - Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team
|
Jan 31, 2024 |
|
PD Dr. med. Luc Biedermann - Targeted Biologic Therapy in Eosinophilic Esophagitis: Practical Strategies for a Changing Therapeutic Landscape
|
Dec 28, 2023 |
|
Yelena Y. Janjigian, MD - Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making
|
Dec 21, 2023 |
|
Beth Sandy, MSN, CRNP, FAPO - Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care
|
Dec 06, 2023 |
|
Josep Tabernero, MD, PhD / Shubham Pant, MD - Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care
|
Dec 06, 2023 |
|
Seema S. Aceves, MD, PhD - Living With Eosinophilic Esophagitis: Recognizing the Burden on Patients and Integrating Targeted Therapy to Improve Outcomes
|
Oct 31, 2023 |
|
Rohit Loomba, MD, MHSc - Hope Is on the Horizon for Nonalcoholic Steatohepatitis: Leveraging the Power of Next Generation Monitoring and Pharmacotherapies
|
Jul 28, 2023 |
|
Elena Elimova, MD, M.Sc., FRcPC - Polishing Management Protocols in HER2-Expressing GI Cancers With Targeted Agents: A Focus on Refining Team-Based Strategies to Individualize BTC and GEA Care
|
Jun 28, 2023 |
|
Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF - Addressing Unmet Nursing Needs in the Management of IBS-C: Understanding the Mechanism of Disease, Newer Therapies, and Coordinated Approaches to Treatment Barriers
|
Jun 01, 2023 |
|
Rachna T. Shroff, MD, FASCO - Getting Personal With Advanced BTC: Insights on Personalizing Upfront and Sequential Care With Immunotherapy and Targeted Agents
|
Mar 01, 2023 |
|
Vivek Subbiah, MD - Seek and You Will Find in Advanced GI Cancers: Identifying and Targeting Uncommon but Actionable Genomic Alterations in Colorectal, Pancreatic, and Other Cancers
|
Mar 01, 2023 |
|
Ghassan Abou-Alfa, MD, MBA - The HCC Revolution Continues: Exploring Evidence-Based Treatment Selection and Sequencing in Advanced Disease and Beyond
|
Mar 01, 2023 |
|
Evan S. Dellon, MD, MPH - What's New in the Management of Eosinophilic Esophagitis: Working Together to Integrate Targeted Treatment Options Into Practice
|
Mar 01, 2023 |
|
Amit Singal, MD, MS - It Takes a Team for HCC: Improving Outcomes Through Multidisciplinary Collaboration and Modern Therapeutics
|
Dec 19, 2022 |
|
Erik P. Sulman, MD, PhD - Harnessing Novel Synergies With Tumor Treating Fields: Insights on Improving Survival With Multimodal Care in Aggressive Tumors
|
Nov 22, 2022 |
|
Sandeep K. Gupta, MD - Updates in Eosinophilic Esophagitis: Exploring Underlying Mechanisms and Integrating Novel Targeted Therapy to Improve Patient Care
|
Nov 17, 2022 |
|
Prof. Arjan Bredenoord - The Latest on New Options for Eosinophilic Esophagitis: Considering Targeted Biologic Therapy
|
Oct 28, 2022 |
|
Jay H. Shubrook, DO, FAAFP, FACOFP - Tools of the Trade: A Practical Guide to Managing NASH
|
Oct 20, 2022 |
|
Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF - An Exploration of Advances in the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation in a Unique Era of Patient Care: Incorporating an Individualized Approach to Help Your Patients Find Relief
|
Sep 27, 2022 |
|
Alexander Drilon, MD - Uncovering Gene Fusions and Other Key Genomic Alterations in Lung, Thyroid, Colon, Breast, and Other Solid Tumors to Enable All Patients to Gain the Full Benefits of Targeted Treatment
|
Aug 25, 2022 |
|
Elena Elez, MD, PhD - Realizing Improved Outcomes in HER2-Positive Gastrointestinal Cancers: New Evidence and Practical Guidance With Targeted Agents
|
Aug 11, 2022 |
|
Yelena Y. Janjigian, MD - Moving the Treatment of Advanced Gastroesophageal Cancers Forward: How Can We Maximize the Benefits of Novel Immunotherapy Approaches?
|
Aug 09, 2022 |
|
Riad Salem, MD, MBA - Making Headway Towards Better Outcomes in Intermediate- to Advanced-Stage Hepatocellular Carcinoma: A Multidisciplinary Tumor Board on Implementing Novel Locoregional and Systemic Approaches
|
Jul 21, 2022 |
|
Richard S. Finn, MD - Setting the Course for the Optimal Management of HCC: Improving Patient Outcomes Through the Integration of Novel Therapeutic Approaches Across the Continuum of Care
|
Jul 12, 2022 |
|
Zev A. Wainberg, MD - Targeting TIGIT to Extend Immunotherapy Benefits to More Cancer Patients: A Strategy to Amplify Immune Response and Enhance or Restore Antitumor Activity
|
Jul 08, 2022 |
|
Kurt A. Schalper, MD, PhD - Decoding the Latest Evidence and Practical Recommendations on Biomarker Testing for New Therapeutic Options Targeting HER2, HER3, and TROP2 in Solid Tumors
|
Jul 04, 2022 |
|
Kimberly A. Brown, MD, FAASLD, FAST, AGAF - Refractory Ascites and Esophageal Variceal Hemorrhage: Practical Guidance to Improve Patient Outcomes
|
Jun 16, 2022 |
|
Linda Ahn, MSN, ANP-BC, AOCNP - Tackling the Practicalities of Antibody–Drug Conjugate Therapy for Solid Tumors: Improving Clinical Care With HER2-, HER3-, and TROP2-Targeted Therapies
|
May 30, 2022 |
|
Kurt A. Schalper, MD, PhD - Progress and Practicalities in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors: What’s New and What You Need to Know and Do
|
May 25, 2022 |
|
John J. Russell, MD - Cancer Control Through Early Blood-Based Detection: Perspectives on Integrating Innovative Multicancer Early Detection Tests in the Primary Care Setting
|
May 05, 2022 |
|
Tanios Bekaii-Saab, MD - Dialing in the Dose: Reviewing Recent Evidence and Team-Based Strategies to Personalize and Optimize Patient Care in Metastatic Colorectal Cancer
|
May 04, 2022 |
|
Anthony R. Mato, MD, MSCE - Solving the Challenge of Tumor Lysis Syndrome: Expert Insight and Guidance on a Challenging Oncologic Emergency
|
Apr 29, 2022 |
|
Milind Javle, MD - Embracing the Era of Individualized Therapy in Advanced Biliary Cancers: Expert Strategies for Applying New and Emerging Targeted Treatment Options Through Precision Medicine
|
Apr 11, 2022 |
|
Richard S. Finn, MD - Mapping the Optimal Treatment Route in HCC: Identifying Best Practices in an Expanding Therapeutic Landscape
|
Mar 29, 2022 |
|
Sam Cheng, MD / Angela Pham, MD - Short Bowel Syndrome IMPACT Initiative: An Initiative to Individualize Treatment and Improve the Pediatric to Adult Healthcare Transition
|
Mar 15, 2022 |
|
Chris A. Liacouras, MD - Expert Perspectives on Improving Early Recognition of Eosinophilic Esophagitis and Examining the Potential Clinical Utility of Emerging Targeted Therapy
|
Jan 31, 2022 |
|
Jennifer Wargo, MD, MMSc - Leveraging Neoadjuvant and Adjuvant Immunotherapy to Break Through the Outcomes Plateau, Prevent Recurrences, and Improve Curability in Early-Stage Cancers
|
Jan 11, 2022 |
|
Evan S. Dellon, MD, MPH - Fulfilling a Need in the Management of Patients With Eosinophilic Esophagitis: An Exploration of Novel and Emerging Therapeutic Options
|
Jan 06, 2022 |
|
Amit Singal, MD, MS - Harmonizing HCC Care With a Multidisciplinary Ensemble: Guidance for the Era of Novel Locoregional, Multimodal, and Systemic Strategies
|
Dec 20, 2021 |
|
Erik P. Sulman, MD, PhD - Implementing Synergistic Multimodal Approaches With Tumor Treating Fields to Extend Survival in Aggressive Cancers
|
Dec 08, 2021 |
|
Ikuo Hirano, MD - On the Cusp of a New Era in Treatment for Eosinophilic Esophagitis: Expert Insights on the Latest Advances in Targeted Therapy
|
Nov 23, 2021 |
|
Prof Eric Van Cutsem, MD, PhD - Putting a Personalized Colorectal Cancer Treatment Algorithm Into Practice: Navigating Practicalities in the Era of Molecularly Defined Care
|
Nov 16, 2021 |
|
Kenneth R. Cooke, MD - Collaborative Strategies for Managing VOD/SOS: Interprofessional Insights on Advances in Diagnosis, Severity Grading, and Treatment
|
Oct 11, 2021 |
|
Manish A. Shah, MD, FASCO - Redrawing the Algorithm in Gastric and GEJ Cancers: Treatment Planning and Sequencing in the Era of Immunotherapy
|
Sep 15, 2021 |